Anti-pneumococcal antibody titre measurement: What useful information does it yield?

Journal of Clinical Pathology

Volumn 60, Issue 4, 2007, Pages 345-350

  Balmer, Paul ^a   Cant, Andrew J ^b   Borrow, Ray ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

23 VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE; 7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; ANTIRETROVIRUS AGENT; BACTERIUM ANTIBODY; MENINGOCOCCAL VACCINE GROUP B POLYSACCHARIDE VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCAL ANTIBODY; PNEUMOCOCCUS POLYSACCHARIDE; POLYSACCHARIDE VACCINE; SALMONELLA TYPHI VI CAPSULAR POLYSACCHARIDE VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ASPLENIA; DRUG EFFICACY; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; KIDNEY DISEASE; PRIORITY JOURNAL; REVIEW; SEROLOGY; SINGLE DRUG DOSE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANTIBODIES, BACTERIAL; HUMANS; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 34247118256     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.041210     Document Type: Review

References (72)

1. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995;33:2759-62.
2. Chief Medical Officer, Chief Nursing Officer and the Chief Pharmacist. Extending Meningitis C vaccine to 20-24 year olds; pneumococcal vaccine for at-risk under 2 year olds. PL/CMO/2002/1, PL/CNO/2002/1, PL/CPHO/2002/1.
3. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-95.
4. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Preventing pneumococcal disease among infants and young children. CDC Morb Mortal Wkly Rep 2000;49:RR-9.
5. Chief Medical Officer, Chief Nursing Officer and the Chief Pharmacist. Important changes to the childhood immunization programme. PL/CMO/2006/1, PL/CNO/2006/1, PL/CPHO/2006/1.
6. Department of Health. Immunisation against infectious diseases - "The Green Book". Chapter 25 Pneumococcal (dated August 2006) [draft]. http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/GreenBook/ GreenBookGeneralInformation/GreenBookGeneralArticle/fs/en?CONTENT_ID= 4097254&chk=isTfGX (accessed 19 Feb 2007).
7. Protcol for the clinical management of cases of invasive pneumococcal disease (IPD) in children targeted for routine or catch-up vaccination with preumococcal conjugate vaccine (Prevenor). http://hpa.org.uk/infections/ topics_az/pneumococcal/vaccine/documents/ClinManageProtocolV3-040107.pdf.
8. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention of pneumococcal disease. CDC Morb Mortal Wkly Rep 1997;46:RR-8.
9. Schiffman G, Douglas RM, Bonner MJ, et al. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol Methods 1980;33:133-44.
10. Ammann AJ, Pelger RJ. Determination of antibody to pneumococcal polysaccharides with chronic chloride-treated human red blood cells and indirect hemagglutination. Appl Microbiol 1972;24:679-83.
11. Hazlewood M, Nusrat R, Kumararatne DS, et al. The acquisition of anti-pneumococcal capsular polysaccharide, Haemophilus influenzae type b and tetanus toxoid antibodies, with age, in the UK. Clin Exp Immunol 1993;93:157-64.
12. Hazlewood MA, Kumararatne DS, Webster AD, et al. An association between homozygous C3 deficiency and low levels of anti-pneumococcal capsular polysaccharide antibodies. Clin Exp Immunol 1992;87:404-9.
13. Siber GR, Priehs C, Madore D. Standardization of antibody assays for measuring the response to pneumococcal infection and immunization. Pediatr Res 1989;8:S84-91.
14. Phipps DC, Strohmeyer S, Quataert S, et al. Standardization of ELISA for the quantitation of antibodies to S. pneumoniae capsular polysaccharides (PnPs). Pediatr Res 1990;27:179A.
15. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn Ps ELISA). Published Online 26 November, 2002. http://vaccine.uab.edu/ ELISA%20Protcol.pdf.
16. Lal G, Balmer P, Stanford E, et al. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to 9 Streptococcus pneumoniae serotypes. J Immunol Methods 2005;296:135-47.
17. Pickering JW, Martins TB, Greer RW, et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol 2002;117:589-96.
18. Musher DM, Watson DA, Baughin RE. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis 1990;161:736-40.
19. Balmer P, North J, Baxter D, et al. Measurement and interpretation of pneumococcal IgG levels for clinical management. Clin Exp Immunol 2003;133:364-9.
20. Nahm MH, Siber GR, Olander JV. A modified Farr assay is more specific than ELISA for measuring antibodies to Streptococcus pneumoniae capsular polysaccharides. J Infect Dis 1996;173:113-18.
21. Misbah SA, Griffiths H, Mitchell T, et al. Antipolysaccharide antibodies in 450 children with otitis media. Clin Exp Immunol 1997;109:67-72.
22. Lakshman R, Gennery AR, Arkwright PD, et al. Assessing immune responses to pneumococcal vaccines. Arch Dis Child 2003;88:648-9.
23. Uddin S, Borrow R, Haeney MR, et al. Total and serotype-specific pneumococcal antibody titres in children with normal immunity and immunodeficiency diseases. Vaccine 2006;24:5637-44.
24. Chief Medical Officer, Chief Nursing Officer and the Chief Pharmacist. Update on the influenza and pneumococcal immunisation programmes PL/CMO/2004/4, PL/CNO/2004/3, PL/CPHO/2004/4.
25. Robbins JB, Lee CJ, Rastogi SC, et al. Comparative immunogenicity of group 6 pneumococcal type 6A and type 6B(26) capsular polysaccharides. Infect Immun 1979;26:1116-22.
26. Vakevainen M, Eklund C, Eskola J, et al. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants. J Infect Dis 2001;184:789-93.
27. Logergard T, Branefors P. Nature of cross-reactivity between Haemophilus influenzae types a and b and Streptococcus pneumoniae types 6A and 6B. Acta Pathol Microbiol Immunol Scand [C], 1983;91:371-6.
28. Bilukha OO, Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep Recomm Rep 2005;54:1-21.
29. Jokhdar H, Borrow R, Sultan A, et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diag Lab Immunol 2004;11:83-8.
30. Ferry BL, Misbah SA, Stephens P, et al. Development of an anti-Salmonella typhi ELISA: assessment of immunocompetence in healthy donors. Clin Exp Immunol 2004;136:297-303.
31. Szu SC, Stone AL, Robbins JD, et al. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med 1987;166:1510-24.
32. Jodar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003;21:3265-72.
33. Shurin PA, Rehmus JM, Johnson CE, et al. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J Pediatr 1993;123:801-10.
34. Siber GR, Thompson C, Reid GR, et al. Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease. J Infect Dis 1992;165(Suppl 1):S129-133.
35. World Health Organisation. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech Rep Ser 2005;927(Annex 2):64-98.
36. Henckaerts I, Goldblatt D, Ashton L, et al. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006;13:356-60.
37. Baker S, Hu BT, Hackell J, et al. Effect of addition of heterologous pneumococcal polysaccharide 22F to the Wyeth/WHO pneumococcal polysaccharide ELISA on IgG assignments for infant sera. Abstracts of the 5th International Symposium on Pneumococci and Pneumococcal Diseases. 2-6 April 2006. Central Australia: Alice Springs Convention Centre, Alice Springs, 2006:285.
38. Rodrigo MJ, Miravitlles M, Cruz MJ, et al. Characterization of specific immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23-valent pneumococcal vaccine in a healthy adult population: proposal for response criteria. Clin Diagn Lab Immunol 1997;4:168-72.
39. Siber GR. Methods for estimating serological correlates of protection. Dev Biol Stand 1997;89:283-96.
40. MacLennan J, Obaro S, Deeks J, et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001;183:97-104.
41. The Australian Immunisation Handbook. 8th edn 2003 (NHMRC). http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/ handbook03.
42. Southern J, Deane S, Ashton L, et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004;11:1100-4.
43. de Roux A, Schmöle-Thoma B, Ahlers N, et al. Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the elderly. Abstracts of the 5th International Symposium on Pneumococci and Pneumococcal Diseases. 2-6 April 2006. Central Australia: Alice Springs Convention Centre, Alice Springs, 2006:248.
44. Granoff DM, Gupta RK, Belshe RB, et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998;178:870-4.
45. MacLennan J, Obaro S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999;17:3086-93.
46. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000;181:761-4.
47. Borgono JM, McLean AA, Vella PP, et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 1978;157:148-54.
48. Torling J, Hedlund J, Konradsen HB, et al. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003;22:96-103.
49. Manoff S, Liss C, Caulfield MJ, et al. Elevated and persistent functional antibody responses in adults ≥65 years of age after a second dose of a 23-valent pneumococcal polysaccharide vaccine. Abstracts of the 5th International Symposium on Pneumococci and Pneumococcal Diseases. 2-6 April 2006. Central Australia: Alice Springs Convention Centre, Alice Springs, 2006:247.
50. Blum MD, Dagan R, Mendelman PM, et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 2000;18:2359-67.
51. Zielen S, Bühring I, Strnad N, et al. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun 2000;68:1435-40.
52. Shrimpton A, Duddridge M, Ziegler-Heitbrock L. Vaccination with polysaccharide-conjugate-vaccines in adult patients with specific antibody deficiency. Vaccine 2006;24:3574-80.
53. Jordano Q, Falco V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004;38:1623-8.
54. Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992;165:553-6.
55. Loeliger AE, Rijkers GT, Aerts P, et al. Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients. FEMS Immunol Med Microbiol 1995;12:33-41.
56. Glaser JB, Volpe S, Aguirre A, et al. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J Infect Dis 1991;164:761-4.
57. Weiss PJ, Wallace MR, Oldfield EC III, et al. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. J Infect Dis 1995;171:1217-22.
58. Falco V, Jordano Q, Cruz MJ, et al. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine 2006;24:2567-74.
59. Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003;112:66- 73.
60. Spoulou VI, Tsoumas DL, Papaevangelou VG, et al. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine 2005;23:5289-93.
61. Aucouturier P, Barra A, Intrator L, et al. Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogenic bone marrow transplantation. Blood 1987;70:779-85.
62. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994;57:677-84.
63. Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogenic hematopoietic cell transplantation. Blood 2003;101:831-6.
64. Antin JH, Guinan EC, Avigan D, et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:213-22.
65. Ljungman P, Engelhard D, de la Camara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005;35:737-46.
66. Landesman SH, Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis 1981;3(Suppl):S184-97.
67. Bernatowska E, Kayhty H, Mikoluc B, et al. Difference response with antibodies to PPV and PCV in asplenic children. Abstracts of the 5th International Symposium on Pneumococci and Pneumococcal Diseases. 2-6 April 2006. Central Australia: Alice Springs Convention Centre, Alice Springs, 2006:207.
68. Musher DM, Ceasar H, Kojic EM, et al. Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis 2005;191:1063-7.
69. Stoehr GA, Rose MA, Eber SW, et al. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. Br J Haematol 2006;132:788-90.
70. Robinson J. Efficacy of pneumococcal immunization in patients with renal disease - what is the data? Am J Nephrol 2004;24:402-9.
71. Wood N, Richmond P, McIntyre P. The use of pneumococcal conjugate vaccine in children with nephritic syndrome. Abstracts of the 5th International Symposium on Pneumococci and Pneumococcal Diseases. 2-6 April 2006. Central Australia: Alice Springs Convention Centre, Alice Springs, 2006:211.
72. Hsu K, Pelton S, Karumuri S, et al. Population-based surveillance for childhood Invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 2005;24:17-23.